Is ORKA or INBX more profitable?

Oruka Therapeutics' return on equity of -26.16% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% Inhibrx Biosciences N/A -563.90% -72.32%

Inhibrx Biosciences (INBX) Competitors

$97.14 -0.44 (-0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$100.93 +3.79 (+3.90%)

As of 06:17 PM Eastern

Compare

INBX vs. ORKA, AMRX, LEGN, CRSP, and TVTX

Should you buy Inhibrx Biosciences stock or one of its competitors? MarketBeat compares Inhibrx Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibrx Biosciences include Oruka Therapeutics (ORKA), Amneal Pharmaceuticals (AMRX), Legend Biotech (LEGN), CRISPR Therapeutics (CRSP), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Oruka Therapeutics has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, indicating that its share price is 241% more volatile than the broader market.

Oruka Therapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Inhibrx Biosciences	$1.30M	1,096.19	-$140.05M	-$8.39	N/A

Oruka Therapeutics presently has a consensus price target of $134.30, suggesting a potential upside of 61.55%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 54.42%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Oruka Therapeutics' return on equity of -26.16% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

In the previous week, Oruka Therapeutics had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 2 mentions for Oruka Therapeutics and 0 mentions for Inhibrx Biosciences. Oruka Therapeutics' average media sentiment score of 0.37 beat Inhibrx Biosciences' score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Oruka Therapeutics	Neutral
Inhibrx Biosciences	Neutral

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Oruka Therapeutics beats Inhibrx Biosciences on 10 of the 14 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Amneal Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.79	$72.06M	$0.38	44.53
Inhibrx Biosciences	$1.30M	1,096.19	-$140.05M	-$8.39	N/A

Amneal Pharmaceuticals presently has a consensus price target of $15.80, suggesting a potential downside of 6.62%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 54.42%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Inhibrx Biosciences' net margin of 0.00%. Amneal Pharmaceuticals' return on equity of -313.96% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market.

In the previous week, Amneal Pharmaceuticals' average media sentiment score of 0.12 beat Inhibrx Biosciences' score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
Inhibrx Biosciences	Neutral

Summary

Amneal Pharmaceuticals beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Inhibrx Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Legend Biotech presently has a consensus price target of $60.23, suggesting a potential upside of 114.80%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 54.42%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Legend Biotech had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 3 mentions for Legend Biotech and 0 mentions for Inhibrx Biosciences. Legend Biotech's average media sentiment score of 0.51 beat Inhibrx Biosciences' score of 0.00 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Legend Biotech	Positive
Inhibrx Biosciences	Neutral

Legend Biotech has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Inhibrx Biosciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.06	-$296.80M	-$0.68	N/A
Inhibrx Biosciences	$1.30M	1,096.19	-$140.05M	-$8.39	N/A

Summary

Legend Biotech beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Inhibrx Biosciences has lower revenue, but higher earnings than CRISPR Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,700.65	-$581.60M	-$6.22	N/A
Inhibrx Biosciences	$1.30M	1,096.19	-$140.05M	-$8.39	N/A

CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus target price of $67.78, suggesting a potential upside of 9.51%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 54.42%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Inhibrx Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 0 mentions for Inhibrx Biosciences. CRISPR Therapeutics' average media sentiment score of 1.05 beat Inhibrx Biosciences' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CRISPR Therapeutics	Positive
Inhibrx Biosciences	Neutral

Summary

CRISPR Therapeutics beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Travere Therapeutics presently has a consensus target price of $52.08, indicating a potential downside of 9.39%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 54.42%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Travere Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.89	-$25.55M	-$0.23	N/A
Inhibrx Biosciences	$1.30M	1,096.19	-$140.05M	-$8.39	N/A

Travere Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, meaning that its share price is 241% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

In the previous week, Travere Therapeutics had 6 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 6 mentions for Travere Therapeutics and 0 mentions for Inhibrx Biosciences. Travere Therapeutics' average media sentiment score of 1.38 beat Inhibrx Biosciences' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Travere Therapeutics	Positive
Inhibrx Biosciences	Neutral

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Travere Therapeutics beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.74B	$6.92B	$12.59B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.63	27.35	24.81
Price / Sales	1,096.19	179.77	507.73	89.92
Price / Cash	N/A	64.18	29.65	49.23
Price / Book	176.62	8.58	11.06	6.50
Net Income	-$140.05M	$23.68M	$3.57B	$336.03M
7 Day Performance	1.72%	4.17%	2.56%	2.68%
1 Month Performance	11.64%	16.07%	7.39%	5.50%
1 Year Performance	496.50%	63.53%	34.13%	25.01%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	1.9252 of 5 stars	$97.14 -0.5%	$150.00 +54.4%	+499.2%	$1.43B	$1.30M	N/A	166
ORKA Oruka Therapeutics	3.1401 of 5 stars	$95.17 +2.9%	$131.30 +38.0%	+576.5%	$5.58B	N/A	N/A	N/A
AMRX Amneal Pharmaceuticals	2.0565 of 5 stars	$17.31 +0.1%	$15.80 -8.7%	+100.4%	$5.52B	$3.02B	45.55	8,500
LEGN Legend Biotech	3.2017 of 5 stars	$28.88 -1.7%	$60.23 +108.6%	-15.4%	$5.46B	$1.03B	N/A	2,965
CRSP CRISPR Therapeutics	1.9238 of 5 stars	$54.59 -3.1%	$67.78 +24.2%	+15.2%	$5.43B	$3.51M	N/A	460	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. ORKA, AMRX, LEGN, CRSP, and TVTX

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Summary

How does Inhibrx Biosciences compare to Amneal Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to Legend Biotech?

Summary

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Summary

How does Inhibrx Biosciences compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. ORKA, AMRX, LEGN, CRSP, and TVTX

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Which has more risk & volatility, ORKA or INBX?

Which has preferable valuation and earnings, ORKA or INBX?

Do analysts recommend ORKA or INBX?

Is ORKA or INBX more profitable?

Does the media favor ORKA or INBX?

Do institutionals & insiders hold more shares of ORKA or INBX?

Summary

How does Inhibrx Biosciences compare to Amneal Pharmaceuticals?

Which has preferable earnings & valuation, AMRX or INBX?

Do analysts rate AMRX or INBX?

Do insiders and institutionals believe in AMRX or INBX?

Is AMRX or INBX more profitable?

Which has more volatility & risk, AMRX or INBX?

Does the media favor AMRX or INBX?

Summary

How does Inhibrx Biosciences compare to Legend Biotech?

Is LEGN or INBX more profitable?

Do analysts prefer LEGN or INBX?

Does the media prefer LEGN or INBX?

Which has more volatility & risk, LEGN or INBX?

Do institutionals and insiders hold more shares of LEGN or INBX?

Which has better earnings & valuation, LEGN or INBX?

Summary

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Do institutionals & insiders hold more shares of CRSP or INBX?

Which has higher valuation & earnings, CRSP or INBX?

Which has more volatility and risk, CRSP or INBX?

Do analysts prefer CRSP or INBX?

Is CRSP or INBX more profitable?

Does the media favor CRSP or INBX?

Summary

How does Inhibrx Biosciences compare to Travere Therapeutics?

Do analysts prefer TVTX or INBX?

Which has stronger valuation & earnings, TVTX or INBX?

Which has more volatility & risk, TVTX or INBX?

Is TVTX or INBX more profitable?

Does the media favor TVTX or INBX?

Do institutionals and insiders have more ownership in TVTX or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools